John T. Curnutte
2016
In 2016, John T. Curnutte earned a total compensation of $2.4M as Executive Vice President, Research and Development at Portola Pharmaceuticals, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $96,863 |
|---|---|
| Option Awards | $959,567 |
| Salary | $430,504 |
| Stock Awards | $818,300 |
| Other | $47,821 |
| Total | $2,353,055 |
Curnutte received $959.6K in option awards, accounting for 41% of the total pay in 2016.
Curnutte also received $96.9K in non-equity incentive plan, $430.5K in salary, $818.3K in stock awards and $47.8K in other compensation.
Rankings
In 2016, John T. Curnutte's compensation ranked 4,172nd out of 14,075 executives tracked by ExecPay. In other words, Curnutte earned more than 70.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,172 out of 14,075 | 70th |
Division Manufacturing | 1,461 out of 5,486 | 73rd |
Major group Chemicals And Allied Products | 441 out of 1,900 | 77th |
Industry group Drugs | 320 out of 1,543 | 79th |
Industry Pharmaceutical Preparations | 251 out of 1,173 | 79th |
Source: SEC filing on April 24, 2017.
Curnutte's colleagues
We found three more compensation records of executives who worked with John T. Curnutte at Portola Pharmaceuticals in 2016.